. Corrigendum to: The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol 2026 Feb 23:noaf291. doi: 10.1093.
PMID: 41729991